GAB2 (Ab-159) Antibody

What is the functional significance of GAB2 Ser159 phosphorylation in cell signaling?

Phosphorylation of GAB2 at Ser159 represents a critical regulatory mechanism in cellular signaling. This site serves as part of a negative feedback loop that attenuates GAB2 signaling. Research indicates that growth factor-induced phosphorylation at Ser159 can modulate the interaction between GAB2 and its binding partners, including 14-3-3 proteins . Specifically, phosphorylation at this site alters the molecular conformation of GAB2, affecting its ability to recruit signaling molecules such as Shp2 and p85. Functionally, this phosphorylation event can downregulate the activation of downstream pathways including the PI3K/Akt and Ras/MAPK cascades, thereby controlling cellular processes such as proliferation, differentiation, and survival .

Which kinases are responsible for phosphorylating GAB2 at Ser159?

Multiple kinases have been implicated in the phosphorylation of GAB2 at Ser159, with the two primary candidates being:

• Akt (Protein Kinase B): Previous studies have established that Akt can directly phosphorylate GAB2 at Ser159 in vitro and in cells. This phosphorylation occurs as part of a negative feedback mechanism following growth factor stimulation .

• RSK (p90 Ribosomal S6 Kinase): Recent research demonstrates that RSK, a downstream effector of the Ras/MAPK pathway, can also phosphorylate GAB2 at Ser160 (Ser159 in human GAB2). Expression of wild-type RSK1 increases Ser160 phosphorylation, while kinase-deficient RSK1 (K112/464R) fails to enhance this phosphorylation beyond levels stimulated by endogenous RSK .

Experimental evidence shows that inhibitors of either the PI3K/Akt pathway (wortmannin) or the MEK/ERK/RSK pathway (PD184352, UO126, BI-D1870) significantly reduce GAB2 Ser159 phosphorylation, suggesting that both pathways contribute to this regulatory event in response to different stimuli .

How can I distinguish between Akt-mediated and RSK-mediated phosphorylation of GAB2 Ser159 in my experimental system?

Distinguishing between Akt and RSK-mediated phosphorylation of GAB2 Ser159 requires a multi-faceted experimental approach:

• Selective inhibitors: Employ isoform-specific inhibitors:

  • For Akt: Use Akt-I-1/2 (which typically produces ~25% inhibition of Ser159 phosphorylation)

  • For RSK: Use BI-D1870 (a specific RSK inhibitor)

  • For upstream kinases: Use wortmannin (PI3K), PD184352 or UO126 (MEK1/2)

• Genetic approaches: Implement kinase knockdown/knockout strategies:

  • Express dominant-negative forms of Akt or RSK

  • Use siRNA-mediated silencing of specific kinase isoforms

  • Create kinase-deficient cell lines using CRISPR/Cas9

• Activation-specific experiments: Selectively activate signaling pathways:

  • Use constitutively active H-Ras G12V to activate the MAPK pathway

  • Employ receptor-specific ligands that preferentially activate either PI3K/Akt or Ras/MAPK pathways

• In vitro kinase assays: Perform direct kinase activity measurements:

  • Purify active Akt and RSK

  • Incubate with GAB2 substrates

  • Compare phosphorylation efficiency at Ser159

The combined results from these approaches will provide a comprehensive understanding of the kinase dependencies in your specific experimental context .

What is the optimal protocol for detecting GAB2 phosphorylation at Ser159 using Western blotting?

For optimal detection of phosphorylated GAB2 at Ser159, follow this detailed protocol:

Sample preparation:

• Lyse cells in buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) to preserve phosphorylation status

• Clear lysates by centrifugation (14,000g, 10 minutes, 4°C)

• Determine protein concentration using BCA or Bradford assay

Immunoprecipitation (for enhanced sensitivity):

• Incubate 500-1000 μg of total protein with 2-5 μg of anti-GAB2 antibody overnight at 4°C

• Add protein A/G beads for 2 hours

• Wash immunoprecipitates 3-4 times with lysis buffer containing phosphatase inhibitors

Western blot procedure:

• Separate proteins on 7.5-10% SDS-PAGE (GAB2 is approximately 90-95 kDa)

• Transfer to PVDF membrane (optimal for phospho-detection)

• Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Incubate with phospho-specific GAB2 (Ser159) antibody at 1:500-1:2000 dilution overnight at 4°C

• Wash with TBST (3 × 10 minutes)

• Incubate with HRP-conjugated secondary antibody

• Visualize using enhanced chemiluminescence

Controls and validation:

• Include positive control: lysates from HT29 cells (suggested positive control)

• Use phosphatase treatment on duplicate samples to confirm specificity

• Reprobe with total GAB2 antibody to normalize phospho-signal

• Consider using phorbol esters (PMA) as a stimulant to maximize Ser159 phosphorylation

This protocol has been optimized based on published research methodologies and manufacturer recommendations .

How do I select the most appropriate anti-phospho-GAB2 (Ser159) antibody for my specific application?

Selection of the optimal phospho-GAB2 (Ser159) antibody requires consideration of multiple factors based on your experimental needs:

For Western blotting applications:

• Prioritize antibodies validated specifically for Western blot with demonstrated specificity

• Consider the working dilution ranges (typically 1:500-1:2000)

• Verify species reactivity matches your experimental model (human, mouse, rat)

For immunohistochemistry applications:

• Select antibodies specifically validated for IHC with recommended dilutions (typically 1:50-1:200)

• Consider the fixation compatibility (formalin-fixed paraffin-embedded vs. frozen sections)

• Check for background staining issues in relevant tissue types

Validation criteria to assess:

• Evidence of specificity through:

  • Detection of a single band at ~95 kDa

  • Loss of signal following phosphatase treatment

  • Reduced signal with Akt or RSK inhibitor pretreatment

  • Absence of signal with S159A mutant GAB2

• Analytical validation metrics:

  • Lot-to-lot consistency

  • Signal-to-noise ratio

  • Linear dynamic range

Based on the search results, specific antibody options include:

• Phospho-GAB2 (Ser159) polyclonal antibody from Invitrogen (PA537587)

• Phospho-GAB2 (Ser159) antibody from Covalab (pab111105)

Each shows specific detection of the phosphorylated form with minimal cross-reactivity .

What strategies can I use to validate the specificity of a GAB2 (Ser159) phospho-specific antibody?

Comprehensive validation of phospho-specific antibodies is essential for reliable research outcomes. For phospho-GAB2 (Ser159) antibodies, implement these validation strategies:

Biological validation:

• Stimulation experiments: Compare unstimulated cells with those treated with growth factors (EGF, serum) or PMA, which should increase Ser159 phosphorylation

• Kinase inhibition: Pretreat cells with:

  • PI3K inhibitors (wortmannin, LY294002)

  • Akt inhibitors (Akt-I-1/2)

  • MEK inhibitors (PD184352, UO126)

  • RSK inhibitors (BI-D1870)
    These should reduce phospho-Ser159 signal

• Genetic manipulation: Use:

  • GAB2 knockout cells as negative controls

  • GAB2 S159A phospho-mutant expression

  • Constitutively active H-Ras (G12V) to enhance phosphorylation

Biochemical validation:

• Phosphatase treatment: Incubate immunoprecipitated GAB2 with lambda phosphatase to demonstrate phospho-specificity

• Peptide competition: Pre-incubate antibody with phospho-Ser159 peptide vs. non-phospho peptide

• Mass spectrometry correlation: Confirm phosphorylation status by LC-MS/MS of immunoprecipitated GAB2

Technical validation:

• Multiple antibody comparison: Test different phospho-Ser159 antibodies on the same samples

• Cross-reactivity assessment: Test on related proteins like GAB1 and GAB3

• Dilution series: Perform antibody titration to identify optimal signal-to-noise ratio

These validation steps ensure that observed signals truly represent phosphorylated GAB2 at Ser159, rather than non-specific binding or cross-reactivity with related phospho-epitopes .

How does the phosphorylation of GAB2 at Ser159 compare with phosphorylation at other regulatory sites (S210, T391)?

The phosphorylation of GAB2 occurs at multiple sites with distinct regulatory functions:

Comparative phosphorylation characteristics:

Functional similarities and differences:

• While all three sites contribute to negative feedback regulation, their relative importance varies by cellular context and stimulation type.

• S210 and T391 appear to function cooperatively - the effects of mutations at both sites on GAB2/Grb2, GAB2/Shc, GAB2/Shp2, and GAB2/pEGFR interactions are additive .

• S159 phosphorylation appears to operate through a mechanism distinct from S210/T391, as a quadruple mutant (S159A, S210A, T391A, S668A) shows enhanced tyrosine phosphorylation compared to the S210A/T391A double mutant .

Methodological considerations:
When studying these phosphorylation events, researchers should consider:

• Using site-specific phospho-antibodies for each position

• Employing site-directed mutagenesis (S→A or T→A) to assess individual site contributions

• Creating combinatorial mutants to detect cooperative effects

• Analyzing temporal dynamics of phosphorylation across multiple timepoints

Understanding the interplay between these phosphorylation sites is crucial for developing a comprehensive model of GAB2 regulation in different signaling contexts .

What are the most common technical challenges when working with phospho-GAB2 (Ser159) antibodies, and how can they be overcome?

Researchers frequently encounter several technical challenges when using phospho-GAB2 (Ser159) antibodies. Here are the most common issues and their solutions:

1. Low signal intensity:

• Cause: Insufficient phosphorylation of GAB2, antibody sensitivity issues, or protein degradation

• Solution:

  • Optimize cell stimulation (use PMA 100 nM for 15-30 minutes or EGF 100 ng/ml)

  • Increase protein loading (50-100 μg for direct WB, 500-1000 μg for IP)

  • Use enhanced chemiluminescence substrates with higher sensitivity

  • Enrich phospho-proteins using titanium dioxide or phospho-enrichment kits

2. High background:

• Cause: Non-specific antibody binding, inadequate blocking, or cross-reactivity

• Solution:

  • Increase blocking time (overnight at 4°C with 5% BSA)

  • Try alternative blocking agents (casein, commercial blockers)

  • Optimize antibody dilution (test 1:500-1:3000 range)

  • Include additional wash steps with higher stringency (0.1% Tween-20 or 0.1% SDS)

3. Multiple bands or unexpected band sizes:

• Cause: Protein degradation, splice variants, or cross-reactivity

• Solution:

  • Use fresh lysates with complete protease inhibitor cocktails

  • Add phosphatase inhibitors immediately (10 mM NaF, 1 mM Na₃VO₄)

  • Confirm GAB2 expression in your cell line using total GAB2 antibodies

  • Use positive controls (HT29 cells or EGF-stimulated cells)

4. Inconsistent results between experiments:

• Cause: Variable phosphorylation status, antibody batch variation, or protocol inconsistencies

• Solution:

  • Standardize cell culture conditions (serum starvation time, confluence)

  • Create standard operating procedures for cell lysis and immunoblotting

  • Include internal loading controls and phosphorylation positive controls

  • Consider using normalization to total GAB2 rather than housekeeping proteins

5. Difficulty distinguishing from other phosphorylated proteins:

• Cause: Antibody cross-reactivity with similar phospho-epitopes

• Solution:

  • Perform parallel experiments with GAB2 knockdown cells

  • Use GAB2 immunoprecipitation before phospho-detection

  • Compare results with those from a second phospho-specific antibody

  • Include GAB2 S159A mutant as negative control

Implementing these technical solutions will significantly improve the reliability and reproducibility of phospho-GAB2 (Ser159) detection in your experimental system .

What is the role of GAB2 Ser159 phosphorylation in oncogenic signaling and how might targeting this modification affect cancer cell biology?

GAB2 Ser159 phosphorylation plays a multifaceted role in oncogenic signaling networks and represents a potential intervention point in cancer research:

Oncogenic signaling mechanisms:

• GAB2 serves as a critical signal amplifier downstream of various growth factor receptors and oncoproteins, including Bcr-Abl, the driver of chronic myeloid leukemia (CML) .

• Phosphorylation at Ser159 functions within a negative feedback loop that normally attenuates GAB2-mediated signaling.

• In cancer contexts, this regulatory mechanism is often dysregulated, contributing to sustained oncogenic signaling.

Cancer-specific roles:

• Breast cancer: GAB2 is frequently overexpressed, and its signaling promotes the growth and metastasis of erbB2-induced mammary tumors . Phosphorylation at Ser159 may regulate this oncogenic activity.

• Chronic myeloid leukemia: GAB2 is required for transformation of myeloid cells by the Bcr-Abl oncoprotein . Altered phosphorylation at Ser159 may affect sensitivity to tyrosine kinase inhibitors like imatinib and dasatinib.

• Other malignancies: GAB2 exhibits transforming activity when relieved of negative feedback control, suggesting that Ser159 phosphorylation may be crucial for preventing oncogenic transformation .

Therapeutic implications:

• Direct targeting: Developing compounds that mimic or enhance Ser159 phosphorylation could potentially suppress GAB2-mediated oncogenic signaling.

• Combination approaches: Inhibitors of kinases that counteract Ser159 phosphorylation might synergize with existing targeted therapies.

• Biomarker potential: Phospho-Ser159 status might predict response to therapies targeting PI3K/Akt or Ras/MAPK pathways.

Experimental approaches to explore therapeutic potential:

• Compare Ser159 phosphorylation levels across cancer cell lines with different GAB2 dependency

• Generate cell lines expressing phosphomimetic (S159D/E) or phosphodeficient (S159A) GAB2 variants

• Assess how manipulating Ser159 phosphorylation affects response to targeted therapies

• Evaluate downstream signaling consequences using phospho-proteomics

These research directions could significantly advance our understanding of GAB2's role in cancer biology and potentially reveal new therapeutic strategies .

How do GAB2 phosphorylation patterns differ between normal and pathological signaling contexts, and what methodological approaches can best characterize these differences?

The phosphorylation pattern of GAB2 exhibits significant differences between normal physiological signaling and pathological contexts such as cancer and inflammatory conditions:

Comparative phosphorylation patterns:

Key differences in pathological contexts:

• Temporal dynamics: Normal signaling typically shows transient phosphorylation of GAB2, while pathological conditions often exhibit sustained phosphorylation patterns .

• Feedback regulation: The negative feedback loop mediated by Ser159, Ser210, and Thr391 phosphorylation may be compromised in cancer cells .

• Kinase dependencies: While normal cells may primarily use Akt for Ser159 phosphorylation, cancer cells might exhibit altered kinase utilization (e.g., RSK-dependent phosphorylation) .

• Integration with other modifications: The interplay between serine/threonine phosphorylation and tyrosine phosphorylation of GAB2 may be distinct in pathological settings .

Methodological approaches for characterization:

• Temporal phospho-profiling:

  • Stimulate cells with growth factors and collect samples across multiple timepoints (0-120 min)

  • Compare phosphorylation kinetics between normal and pathological cells

  • Use phospho-specific antibodies for key sites (Ser159, Ser210, Thr391)

• Quantitative phospho-proteomics:

  • Employ SILAC or TMT labeling for comparative analysis

  • Use titanium dioxide enrichment to capture phosphopeptides

  • Perform LC-MS/MS to identify and quantify phosphorylation sites

  • Compare phosphorylation stoichiometry across multiple sites

• Signalosome analysis:

  • Immunoprecipitate GAB2 from normal and pathological cells

  • Analyze interaction partners by mass spectrometry

  • Compare 14-3-3 protein recruitment and binding partners

  • Assess complex formation with key signaling molecules (Grb2, Shp2, p85)

• Kinase inhibitor profiling:

  • Treat cells with panels of kinase inhibitors targeting PI3K/Akt, MEK/ERK, and other pathways

  • Measure Ser159 phosphorylation response

  • Identify differential kinase dependencies between normal and pathological contexts

• In situ proximity ligation assays:

  • Visualize phospho-GAB2 interactions with binding partners in intact cells

  • Compare interaction patterns between normal and diseased tissues

  • Quantify spatial distribution of signaling complexes